The growth of the global attention deficit hyperactivity disorder (ADHD) treatment market is driven by the prevalence of ADHD. The market attained at value of USD 20.2 billion in 2022. It is further expected to grow at a CAGR of 5.5% during the forecast period of 2023-2031 to attain a value of about USD 32.6 billion by 2031, driven by the launch of various new drugs and awareness of the disease among people.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Attention deficit hyperactivity disorder (ADHD) is defined as a brain disorder in which patients are overactive, impulsive, and inattentive. It is mostly diagnosed in children but it also affects teenagers and adults. People with ADHD may be hyperactive, unable to control their impulses, or have trouble concentrating.
People with ADHD have recurring symptoms such as inattention, hyperactivity, and impulsivity.
Inattentiveness refers to a person's inability to complete a task, maintain focus, or organize themselves, and it is not caused due to resistance or misunderstanding.
Hyperactivity is defined as a person who seems to move constantly, even inappropriately, or who moves, touches, or talks excessively. Hyperactivity in adults can manifest as severe restlessness or excessive talking.
Impulsivity refers to an individual's tendency to act without thinking or have difficulty controlling themselves. Impulsivity can be defined as the need for immediate gratification or the inability to delay gratification.
Inattentiveness is a major symptom of some people with ADHD. Others show signs of impulsivity and hyperactivity.
Some people have both types of symptoms. Men are more likely to have ADHD than women, and women with ADHD are more likely to have symptoms of inattention. Learning disorders, anxiety disorders, conduct disorders, depression, and substance abuse are all common among people with ADHD.
Although the cause of this condition has not yet been determined, several factors are expected to contribute to ADHD, including genetics, prenatal brain damage, and exposure to toxins.
According to the global attention deficit hyperactivity disorder treatment research report, the market can be categorized into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Drugs
Market Breakup by Treatment Type
Market Breakup by Demographic
Market Breakup by Treatment Channel
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The causes of ADHD are not yet clear, but in many cases, there is a genetic link. The factors that drive the growth of the market include the increasing advancement in the medical field to promote premium products for ADHD and increasing susceptibility to mental disorders among people.
However, factors like stringent administrative and regulatory procedures, rising drug prices, and inadequate availability of non-stimulant ADHD drugs are likely to hinder the growth of the market in the coming years.
The contraindications and side effects of ADHD medications can limit the overall market growth. Contraindications and side effects associated with ADHD medications can reduce patients' quality of life and slow the sales growth of the attention deficit hyperactivity disorder (ADHD) treatment market over the forecast period.
Attention deficit hyperactivity disorder medications have contraindications such as allergic reactions to molecules and other medications, medical conditions such as coronary heart disease and bipolar disorder, hallucinations, fast or irregular heartbeats, severe nausea or vomiting, seizures, impotence, and numbness.
In addition, increasing awareness among people regarding mental disorders is expected to drive the growth of the market during the forecast period and is a significant opportunity for growth.
The expansion of the sales force is expected to expand the product range beyond Europe and North America through distribution and collaboration agreements. These opportunities will contribute to the growth of the market in these regions.
Additionally, key companies focused on ADHD treatment research and development are expected to drive the growth of the attention deficit hyperactivity disorder (ADHD) treatment market during the forecast period.
North America dominates the global market due to the high volume of pharmaceutical prescriptions issued each year and the increasing number of product launches. The growing collaboration between players to improve market penetration and expand their offerings will accelerate the growth of the market in the region during the forecast period.
The market is expected to witness significant growth in Europe owing to the rise in mental health vigilance and cases of attention deficit hyperactivity disorder.
Additionally, high adoption of additives and preservatives and improvisation of coverage to treat the condition, in turn, are expected to further propel the growth of the attention deficit hyperactivity disorder (ADHD) treatment market in this region in the coming years.
ADHD therapy has gained significant momentum lately and many effective treatments have been created for a variety of indications. These new therapies and strategies have attracted the attention of the entire biotech and pharmaceutical industry and are considered future hallmarks of the global ADHD market. The fields of Attention Deficit Hyperactivity Disorder treatment are still young compared to other methods.
The United States Food and Drug Administration (FDA) recently approved two drugs that address some of the common problems associated with standard stimulant treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD). Another development is the use of devices to manage ADHD symptoms.
Methylphenidate hydrochloride (Jornay PM), a delayed-release methylphenidate, was approved by the FDA in 2018 and released in 2019. It is different from other methylphenidate-based stimulants.
In April 2021, the FDA approved Viloxazine (Qelbree) for the treatment of ADHD in patients falling in the age groups of 6 to 17 years. Like atomoxetine hydrochloride (Strattera), Qelbree is a selective norepinephrine reuptake inhibitor (SNRI). These drugs are combined with an alpha-2 agonist.
However, these drugs are generally less effective than stimulants in treating ADHD. Combination therapy may be useful in patients.
The Food and Drug Administration also recently approved two devices for treating ADHD in children. Physicians should be aware that FDA approval standards are lower for devices than for drugs. Medicines need to be safe and effective but devices also need to demonstrate safely.
The first device is the Monarch External Trigeminal Nerve Stimulation System (eTNS), a trigeminal nerve stimulator. Unlike vagus nerve stimulators used to control seizures, this treatment does not require surgery. The trigeminal nerve stimulator is located on the face and a small study using data from device manufacturers showed that about half of children with ADHD responded to this device.
In the digital therapy category, the FDA has also approved the use of a video game called EndeavorRx for the treatment of ADHD. The sensory stimulation and motor tasks in games target the neural pathways that control attention and focus. A study sponsored by device manufacturers shows that regular use of the game improves attention and has fewer side effects.
One or both devices may be useful adjuncts in drug and behavioural management.
Thousands of clinical trials are conducted by various medical institutions and pharmaceutical companies. Despite many limitations and obstacles, some ADHD therapies aim to provide effective treatments. Therefore, researchers are developing new targeted therapies by modifying and reconfiguring existing therapies by combining drugs to achieve safer and more effective therapies.
The investigational product candidate KP415 is being developed by KemPharm to treat attention deficit hyperactivity disorder (ADHD). The drug Serdexmethylphenidate (SDX) is a KemPharm's version of d-methylphenidate. The KP415 consists of SDX and immediate-release d-MPH. A New Drug Application (NDA) for KP415 is currently under review with the United States Food and Drug Administration (FDA) with an anticipated PDUFA date of March 2, 2021.
The report gives an in-depth analysis of the key players involved in the attention deficit hyperactivity disorder treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Drug||
|Breakup by Treatment Type||
|Breakup by Demographic||
|Breakup by Treatment Channel||
|Breakup by Distribution Channel of Drugs||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Attention Deficit Hyperactivity Disorder (ADHD) Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
18.104.22.168 Patent Status and Expiry
22.214.171.124.1 Timelines from Drug Development to Commercial Launch
126.96.36.199 New Drug Application
188.8.131.52.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
184.108.40.206 US FDA
220.127.116.11 EU EMA
18.104.22.168 INDIA CDSCO
22.214.171.124 JAPAN PMDA
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
8.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Overview
8.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Analysis
8.2.1 Market Overview
126.96.36.199 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Historical Value (2016-2022)
188.8.131.52 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Forecast Value (2023-2031)
8.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Drug
8.3.1 Market Overview
184.108.40.206.5 Lisdexamfetamine Dimesylate
8.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Treatment Type
8.4.1 Market Overview
220.127.116.11 Psychotherapy Treatment
18.104.22.168.1 Behavioural Therapy
22.214.171.124.2 Cognitive Behavioural Therapy
126.96.36.199.3 Interpersonal Psychotherapy
188.8.131.52.4 Family Therapy
184.108.40.206 Education or Training
220.127.116.11.1 Parent Management Training
18.104.22.168.2 Social Skills Training
22.214.171.124.3 School Based Interventions
8.5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Demographic
8.5.1 Market Overview
8.6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Treatment Channel
8.7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Distribution Channel of Drugs
8.7.1 Market Overview
126.96.36.199 Retail Pharmacy
188.8.131.52 Hospital Pharmacy
8.8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market by Region
8.8.1 Market Overview
184.108.40.206 North America
220.127.116.11 Asia Pacific
18.104.22.168 Latin America
22.214.171.124 Middle East and Africa
9 North America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
11 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
12 Latin America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
13 Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
14 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Takeda Pharmaceutical Company Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Aytu BioPharma, Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Eli Lilly and Company
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Noven Pharmaceuticals Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Alcobra Ltd.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Supernus Pharmaceuticals, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Johnson & Johnson Services Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Novartis AG
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Curemark, LLC
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.11 Impax Laboratories, LLC
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.12 GlaxoSmithKline Plc
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.13 Neos Therapeutics, Inc.
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.14 Highland Therapeutics Inc.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.15 Advanz Pharmaceutical Corp.
15.15.1 Company Overview
15.15.2 Product Portfolio
15.15.3 Demographic Reach and Achievements
15.15.4 Mergers and Acquisitions
16 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market- Drug Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
In 2022, attention deficit hyperactivity disorder treatment market attained a value of USD 20.2 billion.
The market is likely to grow at a CAGR of 5.5% during the forecast period of 2023-2031.
The market is expected to reach a value of USD 32.6 billion by 2031.
The regional markets include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among these regions, North America and Europe are the leading regions.
Based on the drugs, the market can be segmented into stimulant and non-stimulant.
Based on the treatment type, the market can be segmented into psychotherapy treatment, education or training.
Takeda Pharmaceutical Company Limited, Aytu BioPharma, Inc., Eli Lilly and Company, Pfizer Inc., Noven Pharmaceuticals Inc., Alcobra Ltd., Supernus Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Novartis AG, Curemark, LLC, Impax Laboratories, LLC, GlaxoSmithKline Plc, Neos Therapeutics, Inc., Highland Therapeutics Inc., and Advanz Pharmaceutical Corp. are the top companies in the market.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.